Indivior Pharmaceuticals Inc 2025年度报告

☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year ended December 31, 2025OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37835 Indivior Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) 41-2520873(I.R.S. Employer Identification No.) 10710 Midlothian Turnpike Suite 125North Chesterfield, VA 23235(address of principal executive offices)(zip code)Registrant's telephone number, including area code:(804) 379-1040 Securities Registered pursuant to Section 12(b) of the Act: Securities registered pursuant to section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☑No☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes☐No☑ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject tosuch filing requirements for the past 90 days. Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files). Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and"emerging growth company" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying withany new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of itsinternal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountingfirm that prepared or issued its audit report.☑ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant includedin the filing reflect the correction of an error to previously issued financial statements.☑ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-basedcompensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☑ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☑ The aggregate market value of the voting and non-voting common equity held by non-affiliates at June 30, 2025 was approximately $1.83 billionbased on the Nasdaq closing price for such shares on that date. For purposes of this calculation, the registrant has assumed that all of itsdirectors and executive officers were affiliates. As of January 31, 2026, the number of shares of common stock outstanding was 125,065,242. Portions of the Registrant's proxy statement for the 2026 Annual Meeting of Stockholdersare incorporated by reference in Part III of this Form 10-K to the extent described herein. TABLE OF CONTENTS TABLE OF CONTENTS.......................................................................................................................iGLOSSARY...........................................................................................................................................1IMPORTANT CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS.....4ABOUT THIS ANNUAL REPORT......................................................................................................6PART I....................................................................................................................................................7Item 1. Business..............................................................................................................................7Item 1A. Risk Factors......................................................................................................................37Item 1B. Unresolved Staff Comments..........................................................................................78Item 1C. Cybersecurity...................................................................................................................78Item 2.